Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.44 |
| ▸ | DRD3 | P35462 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | BDKRB2 | P30411 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.40 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.39 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6385482 | 0.85 | BDKRB2 (0.51) | BDKRB2MEN1KMT2A | |
| SCHEMBL6384200 | 0.81 | ROCK2 (0.40) | L3MBTL1ROCK2ROCK1ENPP2CXCR3 | |
| SCHEMBL6385697 | 0.81 | BDKRB2 (0.41) | LMNACYP2C19SMN1; SMN2BDKRB2MEN1 | |
| SCHEMBL6390952 | 0.80 | BDKRB2 (0.45) | LMNAACHECYP2C19SMN1; SMN2MAPK1 | |
| SCHEMBL6392038 | 0.79 | OPRM1 (0.49) | LMNACYP2C19MEN1KMT2AL3MBTL1 | |
| SCHEMBL4698590 | 0.79 | BDKRB2 (0.40) | LMNACYP2C19SMN1; SMN2BDKRB2MEN1 | |
| SCHEMBL6387921 | 0.77 | BDKRB2 (0.51) | DRD3SMN1; SMN2BDKRB2KMT2A | |
| SCHEMBL6386312 | 0.77 | EPHX1 (0.42) | DRD3BDKRB2MEN1KMT2AMAPT | |
| SCHEMBL4756002 | 0.77 | ALDH1A1 (0.39) | LMNASMN1; SMN2BDKRB2MEN1KMT2A | |
| SCHEMBL6385497 | 0.76 | HTR2C (0.51) | DRD3BDKRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | claimed |
| US-20050245503-A1 | Therapeutic heterocycles | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245503-A1 | Therapeutic heterocycles | OPRK1, RECQL, OPRM1 | DRD2 873/4885DRD3 696/4885LMNA 2266/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.